In This Section

Program

Wednesday, September 24 

Thursday, September 25 

Friday, September 26 

Saturday, September 27 

Wednesday, September 24

REGISTRATION

3-7 p.m.

WELCOME AND Keynote Lecture

6-6:50 p.m. 

  • 6 p.m. | Keynote Speaker
    Autoimmunity and Cancer: Informing each other through patient-oriented studies  
    Virginia Pascual, Weill Cornell Medical College, New York, New York

Reception 

7-9 p.m. 

Thursday, September 25

Plenary Session 1: Immune Tolerance and Surveillance: Implications for Cancer and Autoimmunity

8-9:50 a.m.

  • 8 a.m. | Lymphatic transport and T cell recirculation maintains chronic responses in cancer
    Amanda Lund, NYU Langone Perlmutter Cancer Center, New York, New York
  • 8:30 a.m. | Dissecting immune tolerance through outliers 
    Mark Anderson, University of California, San Francisco, California
  • 9 a.m. | Regulation of CD8 T cell fates in cancer
    Chen Dong, Westlake University, Hangzhou, Zhejiang, China 

Short talks selected from proffered abstracts

Break 

9:50-10:10 a.m. 

Plenary Session 2: Innate Sensing and Type I Interferon Response in Cancer and Autoimmune Disease 

10:10 a.m.-12 p.m.

  • 10:10 a.m. | Sandra Demaria, Weill Cornell Medicine, New York, New York
  • 10:40 a.m. | Targeting inflammatory memory and chronic interferon signaling in cancer immunotherapy 
    Andy J. Minn, University of Pennsylvania, Philadelphia, Pennsylvania
  • 11:10 a.m. | A genome-wide look at tumor immunoediting  
    Judy Lieberman, Harvard Medical School, Boston, Massachusetts

Short talks selected from proffered abstracts

Free time / Lunch on your own 

12-2 p.m. 

Plenary Session 3: Epigenetic and Genetic Regulation of Cancer Immunity and Autoimmunity  

2-3:50 p.m. 

  • 2 p.m. | Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
  • 2:30 p.m. | Epigenetic regulation of T cells in autoimmunity and anti-cancer immunity
    Maureen Su, UCSF – University of California San Francisco, California
  • 3 p.m. | Elad Ziv, UCSF – University of California San Francisco, San Francisco, California

Short talks selected from proffered abstracts

Break 

3:50-4:10 p.m.

Cancer Immunology (CIMM) Working Group Session

4:10-5:10 p.m.

Panel Discussion: Modeling immune-related adverse events

5:15-6 p.m.

Poster Session A and Reception 

6:15-8:15 p.m.

Friday, September 26

 

Continental Breakfast and Networking Roundtables

7-8 a.m.

Plenary Session 4: Therapeutics at the Intersection of Cancer and Autoimmunity 

8-9:50 a.m.

  • 8 a.m. | Endocrine organs in the crosshairs of the immune system
    Zoe Quandt, University of California, San Francisco, California
  • 8:30 a.m. | Immune checkpoint-inhibitor associated myocarditis: From mouse to humans
    Javid Moslehi, University of California, San Francisco, California

Additional speakers to be announced

Break 

9:50-10:10 a.m.

Plenary Session 5: Role of Microbiota in Immunologic Fitness  

10:10 a.m.-12 p.m.

  • 10 a.m. | Laurence Zitvogel, Gustave Roussy, Paris, France   
  • 10:40 a.m.| Probiotic neoantigen delivery vectors for precision cancer immunotherapy
    Nicholas Arpaia, Columbia University Irving Medical Center, New York, New York
  • 11:10 a.m. | Microbiome control of immunotherapy and adverse events in cancer
    Abigail Overacre, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Short talks selected from proffered abstracts

Free time / Lunch on your own 

12-2 p.m.

Plenary Session 6: CD8 T cells in Cancer and Autoimmunity 

2-3:50 p.m. 

  • 2 p.m. | Ana C. Anderson, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts
  • 2:30 p.m. | E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania 
  • 3 p.m. | T cell stemness and differentiation in autoimmunity and cancer  
    Andrea Schietinger, Memorial Sloan-Kettering Cancer Center, New York, New York 

Short talks selected from proffered abstracts

Break 

3:50-4:10 p.m.

Plenary Session 7: Interplay of B and T cells in Cancer and Autoimmunity 

4:10-6 p.m. 

  • 4:10 p.m. | Modulating B and T cell interactions within and outside of tertiary lymphoid structures for improved anti-tumor immunity  
    Tullia Bruno, University of Pittsburgh, Pittsburgh, Pennsylvania 
  • 4:40 p.m. | Llyod Bod, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts
  • 5:10 p.m. | Ignacio Sanz, Emory University, Atlanta, Georgia 

Short talks selected from proffered abstracts

Poster Session B and Reception 

6:15-8:15 p.m. 

Saturday, September 27

Continental Breakfast and Networking Roundtables

7-8 a.m.

Keynote Address

8-8:45 a.m.

  • 8 a.m. | Targeting Tregs in tumors
    Dario A.A. Vignali, University of Pittsburgh, Pittsburgh, Pennsylvania

Plenary Session 8: Targeting Regulatory T cells in the Tumor Microenvironment and in Autoimmunity  

8:50-10:40 a.m. 

  • 8:50 a.m. | From concept to cure: Developing TregSight for precision immunotherapy 
    Billur Akkaya, Ohio State University, Columbus, Ohio 
  • 9:20 a.m. | CAR-Treg adoptive immunotherapy to treat autoimmune disease
    Jeff Bluestone, University of California, San Francisco, California 

Short talks selected from proffered abstracts

Break

10:40-10:55 a.m.

Plenary Session 9: Activity and Autoimmune Toxicity of Cancer Immunotherapy  

10:55 a.m.-12:45 p.m. 

  • 10:55 a.m. | Predicting, monitoring, and diagnosing immune-related adverse events
    David E. Gerber, University of Texas Southwestern Medical Center, Dallas, Texas 
  • 11:25 a.m. | Chloe Villani, Massachusetts General Hospital (MGH) Center for Cancer Research, Boston, Massachusetts

Additional speakers to be announced

Short talks selected from proffered abstracts